Latest 8-K filings

Grace Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $15.8 million and providing an update on the ongoing efforts to resubmit its New Drug Application for GTx-104.

Venu Holding Corporation announced its second-quarter 2026 financial results, showcasing a substantial increase in total assets and progress on venue development and financing strategies.

Healthy Choice Wellness Corp. announced a 15-year, $1.25 billion take-or-pay lease agreement for 43 MW of IT load capacity at its Oklahoma data center.

Artius II Acquisition Inc. announced its board has decided to liquidate and dissolve the company as it cannot complete its initial business combination within the required timeframe.

Rekor Systems announced Q2 2026 results, showcasing a 23% sequential revenue increase to $12.7 million, improved adjusted gross margin to 56%, and a 79% year-over-year reduction in adjusted EBITDA loss.

SCI Engineered Materials, Inc. has announced a management transition with the resignation of its Chief Financial Officer, Shelby Yohn, who will remain with the company in a new role.

Accelerant Holdings announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valued at over $4 billion, while also reporting strong Q2 2026 financial results.

Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of SYMON-II study enrollment and a strengthened balance sheet with approximately $9.6 million in cash, supporting advancement of its Symphony IL-6 test toward regulatory submission and commercialization.

IREN Limited announced the successful delivery and acceptance of its Horizon 1 AI Cloud deployment by Microsoft, alongside achieving NVIDIA Exemplar Cloud status.

Pyxis Oncology reported Q2 2026 results, announcing a private placement financing of up to $114 million, with approximately $50 million upfront, extending its cash runway into Q2 2027 and providing updates on its MICVO clinical program.

MiNK Therapeutics announced second quarter 2026 financial results and provided positive initial observations from its Phase 2 trial of agenT-797 in acute lung injury, alongside establishing a paid international named-patient access program.

Creative Realities announced record second quarter revenue of $21.5 million and an improved outlook, driven by strong service revenue growth and new major client wins.

Madison Square Garden Sports Corp. announced robust fiscal 2026 fourth quarter and full-year financial results, highlighted by the New York Knicks' NBA Championship win and progress on the proposed spin-off of its New York Rangers business.

Sprinklr, Inc. announced the appointment of Jordi Ribas, Ph.D., a prominent AI and product leader from Microsoft, to its Board of Directors, effective August 17, 2026.

Karyopharm Therapeutics reported Q2 2026 results, with total revenue at $33.4 million, and reaffirmed full-year guidance, while advancing its myelofibrosis program towards an sNDA submission.

Intuitive Machines announced record Q2 2026 revenue of $206 million, up over four times year-over-year, and a record backlog of $1.8 billion, driven by significant new contract awards across commercial, civil, and national security sectors.

Advanced Flower Capital Inc. announced its second quarter 2026 financial results, reporting a net investment income of $3.5 million and an increase in net asset value per share to $8.25.

Cabaletta Bio announced second quarter 2026 financial results, detailing progress in its rese-cel clinical development program for autoimmune diseases and providing updates on manufacturing partnerships.

CorMedix Therapeutics announced robust second quarter 2026 financial results, including $101.9 million in consolidated revenue and $26.0 million in net income, while raising its full-year adjusted EBITDA guidance.

Beacon Financial Corporation presented its Q2 2026 investor update, showcasing improved profitability metrics, strong capital positions, and a strategic focus on commercial lending, while also addressing specific asset quality concerns.

Yesway, Inc. announced strong second quarter 2026 financial results, highlighted by record store contribution, increased net income, and a raised full-year Adjusted EBITDA outlook.

Collegium Pharmaceutical, Inc. has entered into an accelerated share repurchase agreement to buy back $50 million of its common stock as part of an ongoing repurchase program.

Indaptus Therapeutics reported Q2 2026 results, highlighting a significant reduction in operating expenses and net loss, alongside a $12 million private placement, while discontinuing its Decoy20 clinical study and exploring strategic alternatives.

Falcons Beyond Global, Inc. announced its second quarter 2026 financial results, reporting consolidated revenue of $5.6 million, more than double the prior period, alongside a significant Adjusted EBITDA loss.

Abeona Therapeutics announced second quarter 2026 financial results, highlighting a 31% sequential increase in ZEVASKYN net revenue to $11.4 million and securing CMS New Technology Add-On Payment status.

Wabash National Corporation has amended its credit agreement, extending its revolving credit facility to $300 million with an option to increase by $175 million, maturing in August 2031.

Rockwell Medical, Inc. has released an updated corporate presentation on August 13, 2026, providing a general overview of its business and strategic positioning.

ADI Global Distribution Inc. announced record net revenue of $1,286 million for its second quarter of 2026, following its spin-off from Resideo and commencement of trading on the NYSE.

Cellectar Biosciences reported Q2 2026 results, highlighting progress in its iopofosine I 131 and CLR 125 trials, initiation of Phase 3 site activation, and a significant capital raise.

enCore Energy Corp. announced its Q2 2026 financial results, reporting a net loss per share of $0.19 and decreased uranium extraction, while increasing delivery volumes.